« The 27 New Drugs Approved by FDA in 2013 | Main | Open Data Starting with J&J and Yale? »

01/28/2014

Comments

Feed You can follow this conversation by subscribing to the comment feed for this post.

Martin Birchier

While Pfizer's recent disclosures indicate a pervasive difficulty to bring promising Phase 3 drugs to market, its abilities outside the drug market should not be discounted. Pfizer has made some pretty good strides in the medical device field (stents and artificial joints, for example).
Pfizer's 2012 decision to focus was not limited to drug R&D. I wonder whether it might not turn to medical devices to prop itself up in Q1 and Q2 this year.

The comments to this entry are closed.

My Photo
Blog powered by Typepad
Member since 12/2009
Bookmark and Share

July 2014

Sun Mon Tue Wed Thu Fri Sat
    1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30 31    

Innovate on Purpose

In the Pipeline

Life Sci VC


visited 6 states (46.1%)
Create your own visited map of Canada